Biodesix (NASDAQ:BDSX) Director Jack Schuler Purchases 100,000 Shares of Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler bought 100,000 shares of the firm’s stock in a transaction on Tuesday, November 10th. The stock was bought at an average cost of $10.02 per share, for a total transaction of $1,002,000.00. Following the transaction, the director directly owned 655,810 shares of the company’s stock, valued at $6,571,216.20. The trade was a 17.99% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Biodesix Price Performance

Shares of BDSX opened at $9.79 on Friday. Biodesix, Inc. has a 1-year low of $5.26 and a 1-year high of $31.97. The stock has a market cap of $108.57 million, a PE ratio of -3.55 and a beta of 0.65. The firm has a 50-day simple moving average of $24.23 and a two-hundred day simple moving average of $18.88. The company has a debt-to-equity ratio of 5.43, a current ratio of 2.96 and a quick ratio of 2.85.

Biodesix (NASDAQ:BDSX) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.75). Biodesix had a negative net margin of 25.74% and a negative return on equity of 442.34%. The business had revenue of $24.04 million for the quarter, compared to the consensus estimate of $27.48 million. As a group, analysts forecast that Biodesix, Inc. will post -2.95 EPS for the current year.

Key Biodesix News

Investors following BDSX have been watching these news items:

• Positive Sentiment: Director Jack Schuler bought 100,000 shares for about $1.0 million, increasing his direct stake by roughly 18% to 655,810 shares. The purchase may signal confidence in the company. SEC filing
• Negative Sentiment: HC Wainwright cut its EPS estimates across 2026 and 2027, including FY2026 to a loss of $3.13 per share from $2.72 and FY2027 to a loss of $2.18 from $1.57. The revisions point to a weaker expected earnings outlook, even as the firm kept its Buy rating. HC Wainwright estimates article
• Negative Sentiment: Johnson Fistel said it is investigating potential securities claims related to Biodesix’s statements and disclosures after the sharp November 6 stock decline. This is an investigation, not a finding of wrongdoing, but it may add legal and reputational uncertainty. Investigation announcement

Institutional Investors Weigh In On Biodesix

A number of hedge funds have recently added to or reduced their stakes in the business. AIGH Capital Management LLC increased its position in shares of Biodesix by 1.1% during the third quarter. AIGH Capital Management LLC now owns 686,021 shares of the company’s stock worth $20,464,000 after acquiring an additional 7,693 shares during the period. Walleye Capital LLC purchased a new position in Biodesix in the second quarter valued at $1,679,000. GSA Capital Partners LLP purchased a new position in Biodesix in the second quarter valued at $1,060,000. Stempoint Capital LP acquired a new position in Biodesix during the 1st quarter worth $1,015,000. Finally, BlackRock Inc. purchased a new stake in Biodesix during the 2nd quarter worth about $970,000. 20.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. HC Wainwright decreased their price target on Biodesix from $38.00 to $34.00 and set a “buy” rating on the stock in a research note on Monday. Lake Street Capital cut their price objective on Biodesix from $40.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, November 6th. Canaccord Genuity Group boosted their price objective on Biodesix from $27.00 to $35.00 and gave the company a “buy” rating in a report on Monday, August 10th. TD Cowen reissued a “buy” rating and set a $40.00 target price (up from $30.00) on shares of Biodesix in a research note on Tuesday, October 13th. Finally, Weiss Ratings upgraded Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 8th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.20.

Biodesix Company Profile

Biodesix, Inc. is a molecular diagnostics company focused on blood-based testing and data-driven tools for lung disease, particularly lung cancer. The company develops and provides diagnostic tests intended to help clinicians assess lung nodules and inform treatment decisions. Its products include the Nodify Lung suite, which is designed to support assessment of lung nodules, and VeriStrat, a blood-based test that helps inform treatment decisions for patients with non-small cell lung cancer. Biodesix also offers laboratory and diagnostic services to pharmaceutical and biotechnology companies.